The tetrazole ring at the heart of these molecules is a five-membered structure built from one carbon atom and four nitrogen atoms, and it has long occupied a privileged position in medicinal chemistry. Its most celebrated property is that it acts as a bioisostere of the carboxylic acid group, meaning it can stand in for that common acidic motif while conferring better metabolic stability, tuned lipophilicity, hydrogen-bonding capacity and membrane permeability. The ring’s track record in the clinic is substantial: the β-lactam antibiotics cefotetan and cefotiam, the oxazolidinone antibiotic tedizolid phosphate, the antihypertensive losartan, the antiplatelet drug cilostazol, the leukotriene antagonist tomelukast, the anticonvulsant cenobamate and the antifungal candidate TAK-456 all carry a tetrazole unit that contributes to receptor recognition, binding affinity and pharmacokinetic behaviour. That pedigree made the scaffold a natural choice for a team hunting structurally novel antibacterial agents capable of sidestepping the resistance mechanisms—target modification, enzymatic degradation, reduced membrane permeability and active efflux—that steadily erode the value of conventional antibiotics.

The synthetic strategy is as much a story as the molecules themselves. Multicomponent reactions are prized in drug discovery because they stitch together three or more building blocks in one operation, delivering structural diversity with operational simplicity and high atom economy. The Ugi–azide variant used here condenses four partners: an aldehyde, a primary aromatic amine, trimethylsilyl azide and tert-butyl isocyanide. In the reported protocol, 2-(4-chloro-2-formylphenoxy)acetonitrile reacts with a range of substituted anilines, trimethylsilyl azide and tert-butyl isocyanide in anhydrous methanol at ambient temperature. The mechanism unfolds in a cascade: the aldehyde and amine first form an imine, or Schiff base, while the silyl azide undergoes methanolysis to release hydrazoic acid. The isocyanide then attacks the protonated imine to generate a nitrilium ion, the azide anion strikes the nitrilium carbon to form an azido-imidoyl intermediate, and an intramolecular 1,3-dipolar [3+2] cycloaddition closes the tetrazole ring. The bulky tert-butyl group steers the reaction toward N-1 regioselective ring formation, delivering the desired 1,5-disubstituted α-aminotetrazoles cleanly.

Solvent choice proved decisive. In a systematic screen using compound 5a as the model substrate, the non-polar solvent toluene was completely ineffective, while chlorinated solvents such as dichloromethane and chloroform managed only trace-to-poor conversions of 28 percent or less even after 48 to 72 hours. Polar aprotic solvents including tetrahydrofuran, acetonitrile and dimethylformamide gave moderate yields of 32 to 58 percent with incomplete product precipitation. Ethanol and isopropanol performed better but still required two days. Methanol emerged as the clear winner, delivering an 85 percent yield within 18 hours, accompanied by spontaneous, clean precipitation of the product. Under the optimized conditions—one millimole scale in eight millilitres of anhydrous methanol at room temperature for 18 to 24 hours—all ten derivatives were isolated in excellent yields of 84 to 88 percent simply by washing the precipitated solid with ice-cold methanol and anhydrous hexane, avoiding chromatography altogether.

Structural confirmation rested on a battery of spectroscopic techniques. Fourier-transform infrared spectra showed broad N–H stretching between 3311 and 3398 inverse centimetres, a nitrile absorption near 2230 inverse centimetres and tetrazole C=N vibrations between 1600 and 1660 inverse centimetres. Proton NMR spectra recorded at 500 megahertz in deuterated DMSO displayed the diagnostic methine proton as a doublet between 5.86 and 6.46 parts per million, the tert-butyl singlet at roughly 1.7 parts per million and the phenoxy methylene singlet near 5.2 parts per million. Carbon-13 NMR placed the quaternary tetrazole carbon at 152 to 154 parts per million, and mass spectrometry confirmed molecular ion peaks matching the calculated formulae for every compound in the series.

The biological evaluation covered four bacterial strains—Streptococcus pyogenes, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa—and two fungal species, Aspergillus clavatus and Candida albicans, using minimum inhibitory concentrations determined by the agar dilution method against the reference antibiotics gentamicin and ketoconazole. Compound 5c, bearing an ortho-fluorophenyl substituent, stood out as the most potent antibacterial agent, with MIC values ranging from 39.67 to 170 micrograms per millilitre across strains and small error bars indicating excellent reproducibility. Against Staphylococcus aureus, 5c reached 52.33 micrograms per millilitre, the lowest value in the series, while compounds 5b, 5i and 5j also performed respectably. The antifungal picture was far less encouraging: activity against A. clavatus and C. albicans was limited and generally far weaker than ketoconazole, suggesting the scaffold is selective for bacterial targets rather than a broad-spectrum antimicrobial.

The structure–activity relationship that emerged from the data is clear and chemically intuitive. Electron-withdrawing halogen substituents, particularly fluorine placed at the ortho position, enhance antimicrobial potency, presumably by increasing lipophilicity and strengthening interactions with microbial targets, whereas bulky substituents diminish activity. The authors rank the series as 5c greater than 5b, 5i and 5j, followed by 5a, 5g, 5d, 5e, 5f and 5h. Notably, compound 5d showed substantial variability against A. clavatus, with a value of 266.67 plus or minus 213.85 micrograms per millilitre, producing a non-significant difference from ketoconazole that the authors attribute to large variation among replicate observations rather than genuine equivalence.

To probe mechanism, the team docked all ten compounds into penicillin-binding protein 2a, the enzyme that renders methicillin-resistant Staphylococcus aureus, or MRSA, impervious to β-lactam antibiotics and is therefore a clinically validated target for anti-MRSA drug development. Using AutoDock Vina against the crystal structure with PDB identifier 3ZG5, every compound showed strong predicted binding free energies between −7.1 and −7.9 kilocalories per mole, all exceeding the −6.6 kilocalories per mole calculated for gentamicin. Compound 5f, carrying a para-nitrophenyl group, achieved the highest affinity at −7.9 kilocalories per mole, forming hydrogen bonds with lysine 215 and aspartate 367, while compound 5a ranked second at −7.8 and additionally formed a notable halogen bond with aspartate 367. Three residues—lysine 215, proline 370 and glutamate 379—were engaged consistently across the series, marking them as critical contacts for future optimization. The authors candidly note that docking scores and experimental MIC values correlated only partially, with the discrepancy for 5f likely reflecting membrane permeability and efflux effects that docking calculations cannot capture.

Computational ADME profiling using the pkCSM platform rounded out the assessment and delivered a largely encouraging pharmacokinetic forecast. All ten compounds were predicted to achieve high human intestinal absorption of 90.9 to 100 percent, dramatically better than gentamicin’s predicted 19.2 percent, pointing to favourable oral bioavailability for a class of molecules that could otherwise require injection. Aqueous solubility was moderate, and every compound was predicted to inhibit P-glycoprotein, an intriguing property that could suppress efflux-mediated resistance in bacteria. Distribution predictions showed low blood–brain barrier penetration, a desirable trait for peripherally acting antibacterial agents, alongside moderate-to-high plasma protein binding. Metabolically, all compounds were substrates of CYP3A4 but not CYP2D6, a favourable safety attribute, although predicted inhibition of CYP2C19, CYP2C9 and CYP3A4 flags a need for careful drug–drug interaction evaluation during preclinical development. Excretion profiles indicated moderate-to-low systemic clearance, consistent with a prolonged duration of antibacterial action.

Taken together, the study positions the α-aminotetrazole scaffold as a promising, drug-like antibacterial pharmacophore that merits focused medicinal chemistry optimization and eventual in vivo evaluation. The one-pot Ugi–azide synthesis, with its excellent yields, mild conditions and purification by simple washing, offers medicinal chemists an efficient platform for rapidly exploring analogues around the active ortho-halogenated leads, particularly compound 5c. With MRSA still driving prolonged hospitalizations, rising mortality and escalating healthcare costs worldwide, and with the global burden of bacterial antimicrobial resistance estimated in the hundreds of thousands of deaths annually, even modest advances in scaffold design carry weight. The Indian team’s work demonstrates how a century-old multicomponent reaction, a clinically proven heterocycle and modern computational screening can converge to generate credible new candidates in the fight against resistant bacteria—while honestly acknowledging that the distance from a docking score to a bedside drug remains long and demanding.

Subject of Research: Synthesis of disubstituted α-aminotetrazole derivatives via the Ugi–azide reaction and their antibacterial activity, molecular docking against MRSA PBP2a, and ADME profiling

Article Title: Synthesis of novel disubstituted tetrazole scaffolds via the Ugi TMS-N3 reaction and their antimicrobial evaluation molecular docking and ADME profiling

Article References: Gohil, R., Khoyanee, A., Ramani, H., & Khunt, R. (2026). Synthesis of novel disubstituted tetrazole scaffolds via the Ugi TMS-N3 reaction and their antimicrobial evaluation molecular docking and ADME profiling. Discover Chemistry, 3(1), Article 560. https://doi.org/10.1007/s44371-026-01018-4

Image Credits: AI Generated

DOI: 10.1007/s44371-026-01018-4

Keywords: tetrazole, Ugi-azide reaction, multicomponent reaction, antimicrobial resistance, MRSA, PBP2a, molecular docking, ADME profiling, medicinal chemistry, antibacterial agents, structure-activity relationship, heterocyclic chemistry